Frontline brentuximab vedotin in breast implant-associated anaplastic large-cell lymphoma.

Clinical case reports 2018 Vol.6(4) p. 634-637

Alderuccio JP, Desai A, Yepes MM, Chapman JR, Vega F, Lossos IS

관련 도메인

Abstract

We report a woman who developed BIA-ALCL 9 years after saline implant placement. The lymphoma manifested as a mass lesion associated with axillary lymphadenopathy. She was successfully treated with brentuximab vedotin with minimal toxicity. Brentuximab vedotin may be a promising frontline therapeutic modality for patients with BIA-ALCL.

추출된 의학 개체 (NER)

유형영어 표현한국어 / 풀이UMLS CUI출처등장
합병증 bia-alcl 보형물연관 역형성대세포림프종 dict 2
해부 brentuximab vedotin scispacy 1
해부 breast 유방 dict 1
재료 saline implant 생리식염수 보형물 dict 1
약물 brentuximab vedotin C2973446
brentuximab vedotin
scispacy 1
약물 saline scispacy 1
질환 breast implant-associated anaplastic large-cell lymphoma C4528210
Breast implant-associated anaplastic large-cell lymphoma
scispacy 1
질환 lymphoma C0024299
Lymphoma
scispacy 1
질환 toxicity C0040539
Toxicity aspects
scispacy 1
질환 BIA-ALCL 9 scispacy 1
기타 axillary lymphadenopathy scispacy 1
기타 patients scispacy 1

🔗 함께 등장하는 도메인

이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들

관련 논문